We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Impath Clients to Benefit from Cell Analysis' QCA System

By HospiMedica staff writers
Posted on 16 Apr 2004
Under the terms of a recently announced agreement, the Quantitative Cellular Assessment (QCA) system of Cell Analysis (Evanston, IL, USA) will be provided exclusively to the clients of Impath, Inc. More...
(New York, NY, USA). Terms were not disclosed.

The QCA system has been cleared by the U.S. Food and Drug Administration (FDA) for estrogen receptor (ER) markers in breast cancer and is awaiting clearance for the oncoprotein Her2/neu. In addition, the system has been designed to analyze all nuclear, membranous, and cytoplasmic immunohistochemical (IHC) markers. The QCA system objectively analyzes tumor cells for predictive and prognostic markers using quantitative image analysis of nuclear and membrane antigens, enabling more precise, targeted therapeutic decision-making.

"QCA is an important new technology that can help improve the quality of information available to pathologists, researchers, and oncologists, so they can make the best decisions for their patients,” explained Joel Herm, CEO of Cell Analysis. The company is a privately held life sciences company that is developing affordable, easy-to-use image analysis tools for studying cancer cells.

"Cell Analysis' QCA system and built-in control of IHC stained tissue slides facilitate reproducibility and rapid turnaround while removing the clinician's perceived limitation of manual inspection,” said Carter H. Eckert, chairman and CEO of Impath. The company states it is in the business of improving outcomes for cancer patients. Its Physician Services uses sophisticated technologies to provide patient-specific cancer diagnostics and prognostic services to pathologists and oncologists.




Related Links:
Impath
Cell Analysis

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Patient Monitoring System
AlarmSense
New
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Even though the team’s new bioelectronic is only about the size of a fingertip, it could offer an effective and biocompatible approach to addressing high blood pressure (photo courtesy of Tao Zhou/Penn State)

Stretchable Bioelectronic Implant Lowers Blood Pressure in Preclinical Study

Hypertension, or high blood pressure, drives major cardiovascular morbidity and affects nearly half of adults in the United States. About one in ten patients develop drug‑resistant hypertension that persists... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.